Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis […]
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England […]
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in […]
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard […]
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND […]
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior […]
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy […]
Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford […]
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. […]
100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily […]
